ClinicalTrials.gg
RecruitingNCT04688190CHOICE-MIUpdated May 7, 2026

CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry

An observational study in Mitral Regurgitation, Mitral Valve Disease and Mitral Annular Calcification, sponsored by Universitätsklinikum Hamburg-Eppendorf. Recruiting at 43 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Observational

How we know

From the registry’s dates

  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 81 studies in Mitral Valve Insufficiency with a site in Germany — 24 open to participants now, 32 under way, none of them phase 3. Mitral Valve Insufficiency · Germany.

Planned enrollment
6th of 33
1,000 · median 214
Started
2020
with 9 others
Observational
33 of 81
12 open now
Primary completion
2030-12
later than 26 of 31 live
Registered
59th of 81
by date

Among the 81 studies in Mitral Valve Insufficiency with a site in Germany, this one is the 6th largest by planned enrollment of the 33 observational ones that give a count, is one of 10 that started in 2020, is one of 33 observational ones, reaches primary completion later than 26 of the 31 other live ones, and was the 59th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

24 of the 81 studies in Mitral Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Mitral Valve Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

This multinational, investigator-initiated registry aims to investigate clinical outcomes of patients undergoing transcatheter mitral valve replacement (TMVR). The registry primarily focuses on patients treated with TMVR in real-world clinical practice.

Patients evaluated for TMVR but not undergoing the procedure are no longer systematically included. Historical data may include such patients who subsequently underwent alternative treatments, including transcatheter edge-to-edge repair, mitral valve surgery, or medical/conservative therapy.

03

Conditions studied

  • Mitral Regurgitation
  • Mitral Valve Disease
  • Mitral Annular Calcification
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study aimes to include all patients with significant mitral insufficiency, who underwent screening for possible transcatheter mitral valve implantation (TMVI), irrespective of the subsequent therapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • mitral insufficiency
  • patient underwent screening for TMVI
  • echocardiography data at baseline (and after TMVI, E2E and surgery)
  • follow-up of at least 30 days

Exclusion criteria

Exclusion Criteria:

- age under 18 years

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Transcatheter Mitral Valve Replacement (TMVR)

    Patients with successful TMVR screening, who underwent Transcatheter Mitral Valve Replacement subsequently. All devices may be included.

  • Mitral transcatheter edge-to-edge repair (M-TEER)

    Patients with TMVR screening failure, who subsequently underwent interventional mitral valve edge-to-edge repair. Update: These patients are currently no longer systematically included.

  • Mitral valve surgery (Surgery)

    Patients with TMVR screening failure, who subsequently underwent mitral valve surgery (i.e., mitral valve repair or replacement). Update: These patients are currently no longer systematically included.

  • Medical/conservative therapy

    Patients with TMVR screening failure, who subsequently underwent conservative or optimal medical therapy. Update: These patients are currently no longer systematically included.

06

What researchers measure

Primary outcomes

  1. Mitral insufficiency grade 2+ or more

    Mitral insufficiency measured by transthoracic echocardiography. Assessment of MI severity according to current guidelines (ESC/EACTS and ACC/AHA) for valvular heart disease.

    Time frame: 12 months

  2. Freedom from device-related complications

    Time frame: 30 days

Secondary outcomes

  1. Combined all-cause mortality or rehospitalization for congestive heart failure

    Time frame: 12 months

  2. All-cause mortality

    Time frame: 12 months

  3. Cardiovascular mortality

    Time frame: 12 months

  4. Rehospitalization for congestive heart failure

    Incidence of new-onset or worsening signs and symptoms of heart failure that required urgent therapy and resulted in hospitalization, e.g. as assessed by patient interviews.

    Time frame: 12 months

  5. Combined cardiovascular mortality or rehospitalization for congestive heart failure

    Time frame: 12 months

  6. Unplanned mitral valve intervention

    Incidence of unplanned surgical or transcatheter re-intervention, heart transplantation or left ventricular assist device implantation, e.g. as assessed by patient interviews.

    Time frame: 12 months

  7. Combined all-cause mortality, rehospitalization for congestive heart failure or unplanned mitral valve intervention

    Time frame: 12 months

  8. Combined cardiovascular mortality, rehospitalization for congestive heart failure or unplanned mitral valve intervention

    Time frame: 12 months

  9. New York Heart Association (NYHA) stage III or IV

    Assessment of New York Heart Association (NYHA) classification stage (in- or outpatient) after 12 months follow-up, as assessed by patient interviews.

    Time frame: 12 months

07

Study locations

43 of 43 sites recruiting
08

References and documents

Publications

  • Ludwig S, Coisne A, Hamzi K, Ben Ali W, Scotti A, Koell B, Duncan A, Makkar R, Akodad M, Bleiziffer S, Nickenig G, Kaneko T, Ruge H, Adam M, Sondergaard L, Dahle G, Taramasso M, Walther T, Kempfert J, Obadia JF, Chehab O, Tang GHL, Goel S, Fam N, Denti P, Praz F, von Bardeleben RS, Hausleiter J, Latib A, Conradi L, Modine T, Pezel T, Granada JF; CHOICE-MI Investigators. Phenotypic clustering analysis of patients rejected for mitral valve interventions: implications for future transcatheter technologies. Eur Heart J Cardiovasc Imaging. 2025 Jul 31;26(8):1452-1463. doi: 10.1093/ehjci/jeaf141. PubMed 40329826 ↗
  • Coisne A, Ludwig S, Scotti A, Ben Ali W, Weimann J, Duncan A, Webb JG, Kalbacher D, Rudolph TK, Nickenig G, Hausleiter J, Ruge H, Adam M, Petronio AS, Dumonteil N, Sondergaard L, Adamo M, Regazzoli D, Garatti A, Schmidt T, Dahle G, Taramasso M, Walther T, Kempfert J, Obadia JF, Redwood S, Tang GHL, Goel S, Fam N, Metra M, Andreas M, Muller DW, Denti P, Praz F, von Bardeleben RS, Leroux L, Latib A, Granada JF, Conradi L, Modine T; CHOICE-MI Investigators. Outcomes Following Transcatheter Mitral Valve Replacement Using Dedicated Devices in Patients With Mitral Annular Calcification. JACC Cardiovasc Interv. 2024 Sep 23;17(18):2141-2153. doi: 10.1016/j.jcin.2024.07.038. Epub 2024 Sep 4. PubMed 39243262 ↗
  • Ludwig S, Conradi L, Cohen DJ, Coisne A, Scotti A, Abraham WT, Ben Ali W, Zhou Z, Li Y, Kar S, Duncan A, Lim DS, Adamo M, Redfors B, Muller DWM, Webb JG, Petronio AS, Ruge H, Nickenig G, Sondergaard L, Adam M, Regazzoli D, Garatti A, Schmidt T, Andreas M, Dahle G, Walther T, Kempfert J, Tang GHL, Redwood S, Taramasso M, Praz F, Fam N, Dumonteil N, Obadia JF, von Bardeleben RS, Rudolph TK, Reardon MJ, Metra M, Denti P, Mack MJ, Hausleiter J, Asch FM, Latib A, Lindenfeld J, Modine T, Stone GW, Granada JF; CHOICE-MI and the COAPT Trial Investigators. Transcatheter Mitral Valve Replacement Versus Medical Therapy for Secondary Mitral Regurgitation: A Propensity Score-Matched Comparison. Circ Cardiovasc Interv. 2023 Jun;16(6):e013045. doi: 10.1161/CIRCINTERVENTIONS.123.013045. Epub 2023 May 16. PubMed 37194288 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2020 (actual). Primary completion is estimated for Dec 2030, 121 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2020
First posted
Dec 29, 2020
StartActual
Nov 1, 2020
Primary completionEst.
Dec 1, 2030
CompletionEst.
Dec 31, 2030
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04688190
Responsible party
Sebastian Ludwig (Sebastian Ludwig, M.D., Principal Investigator, Universitätsklinikum Hamburg-Eppendorf) — Principal investigator
First posted
Dec 29, 2020
Start date
Nov 1, 2020
Primary completion
Dec 1, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
May 7, 2026

Study contacts

Sebastian Ludwig, MD
Contact
se.ludwig@uke.de
+494074100
Lena Strotmann, MD
Contact
L.Strotmann@uke.de
+4074100
Lenard Conradi, MD
principal investigator · University of Cologne
Thomas Modine, MD
principal investigator · University Hospital, Bordeaux
Sebastian Ludwig, MD
principal investigator · University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf
Juan F Granada, MD
principal investigator · Cardiovascular Research Foundation, New York, USA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion